DisGeNET - a database of gene-disease associations

response to simvastatin, C3894553

Source: ALL

Results per page

Gene

Disease

Variant

Source

Association Type

Semantic type

Protein Class

Disease Class

Type

Original DB

Consequence

DSI _v

DPI _v

pLI

EI _vda

EL _gda

Score _vda

PMID

PMID Year

AF_EXOME

Num. PMIDs

Num. SNPs_gda

AF_GENOME

Variant

Gene

Risk Allele

Score _vda

Association Type

Original DB

Sentence supporting the association

PMID

PMID Year

dbSNP:

rs113816795

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs114007472

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs116616455

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs117168171

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs138270994

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs146807753

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs250567

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs2823310

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs62210650

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs6847878

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs75298135

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs76043556

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs80147136

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs9472719

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs72804453

BICC1

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs13064411

CFAP44

0.700

GeneticVariation

GWASCAT

Ancestry and other genetic associations with plasma PCSK9 response to simvastatin.

25089948

2014

dbSNP:

rs34030778

CLN8

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs145010525

DARS1

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs181126208

EDARADD

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs80333777

FBXL7

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs2607653

FGF14

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs16914931

GABBR2

0.700

GeneticVariation

GWASCAT

Ancestry and other genetic associations with plasma PCSK9 response to simvastatin.

25089948

2014

dbSNP:

rs10034465

LINC02484

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs112209655

LOC102724680

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018

dbSNP:

rs115990514

LOC107986066

0.700

GeneticVariation

GWASCAT

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

28736931

2018